百时美与Allied Minds成立合资公司——加速早期创新向临床转化

2014年8月5日讯 /生物谷BIOON/ --百时美施贵宝（BMS）和Allied Minds公司8月4日宣布，双方联合创建合资公司Allied-Bristol生命科学公司，该合资公司将专注于将来自全美一流大学及研究机构的早期创新，向药物研究及临床前开发转化。

Allied-Bristol生命科学公司将专注于高效和有效地将高效科研机构的发现转化为候选药物，用于临床开发，并最终获批用于解决严重的疾病。对于合资公司确定的项目，高校科研人员将能够获取百时美施贵宝的药物发现专业知识以及Allied Minds公司的财务和管理经验。

根据协议条款，双方已共同成立并资助Allied-Bristol生命科学公司，该合资公司将与高校研究人员合作，鉴定具有治疗和商业潜力的重大发现，同时为这些早期的机会提供必要的研发支持，将其从最初的可行性向临床前候选药物推进。此外，Allied Minds和百时美施贵宝还将联合成立新的公司，来开展可信性研究和全期（all-phase）发现项目。根据事先约定的条款，一旦某个项目成功鉴定出一种临床前候选药物，百时美施贵宝将拥有收购来自Allied-Bristol生命科学公司的选择权。

Allied Minds是一家创新的美国科学和技术开发及商业化公司，自2006年运营以来，该公司一直从事创立、资助、管理和构建基于美国知名大学和联邦政府科研机构开发的创新技术的产品和业务，该公司已与全美超过33所著名大学和美国国防部和能源部下属32个联邦研究中心和实验室达成合作。目前，Allied Minds在美国运营18家公司。（生物谷Bioon.com）

英文原文：Allied Minds and Bristol-Myers Squibb Form New Enterprise to Advance Discoveries of Biopharmaceutical Innovations at Leading U.S. Academic Research Institutions

Allied-Bristol Life Sciences LLC to identify and speed development of promising science and technologies

Unique collaboration focused on transforming early-stage academic innovation to therapeutic candidates for clinical study

Monday, August 4, 2014 2:00 am EDT

BOSTON & NEW YORK--(BUSINESS WIRE)--Allied Minds (LSE: ALM) and Bristol-Myers Squibb Company (NYSE: BMY) today announced the formation of Allied-Bristol Life Sciences LLC, a new jointly owned enterprise created to identify and foster research and pre-clinical development of biopharmaceutical innovations from leading university research institutions across the U.S.

Allied-Bristol Life Sciences LLC will focus on efficiently and effectively converting discoveries from university research institutions into therapeutic candidates for clinical development, and ultimately approved therapies that address serious diseases. For programs identified by the new enterprise, university researchers will be able to access Bristol-Myers Squibb’s drug discovery research expertise, and Allied Minds’ financial and management experience.

“The innovations developed in U.S. research institutions represent an important resource for scientific advancement, as well as economic development and financial returns,” said Chris Silva, Chief Executive Officer of Allied Minds. “Our partnership with Bristol-Myers Squibb combines complementary strengths, resources, reach and expertise to create an exciting new paradigm in the drug development space.”

“Allied-Bristol Life Sciences LLC brings together cutting-edge ideas, BioPharma experience and drug discovery expertise focused on maximizing the potential of new scientific approaches to addressing serious disease,” said Carl Decicco, senior vice president and Head of Discovery, Bristol-Myers Squibb. “We believe this new venture will enhance the translation of early-stage academic research and will ultimately help advance important potential new medicines more efficiently.”

Under the terms of the agreement, the companies have jointly formed and funded Allied-Bristol Life Sciences LLC, which will work with university researchers to identify discoveries it believes has promising therapeutic and commercial potential, and will support the research and development needed to take these early-stage opportunities from initial feasibility to pre-clinical candidacy. Allied Minds and Bristol-Myers Squibb together will form and fund new companies to conduct feasibility and full-phase discovery programs. Once a program succeeds in identifying a pre-clinical candidate, Bristol-Myers Squibb will have the option to acquire the company from Allied-Bristol Life Sciences LLC under pre-agreed terms.

About Allied Minds

Allied Minds (LSE: ALM) is an innovative U.S. science and technology development and commercialization company. Operating since 2006, the company forms, funds, manages and builds products and businesses based on innovative technologies developed at leading U.S. universities and federal research institutions. Allied Minds serves as a diversified holding company that supports its businesses and product development with capital, central management and shared services. More information about the Boston-based company can be found at www.alliedminds.com.

Allied Minds’ investment model is to form, fund, manage and build companies and jobs for the long term. The company takes a majority ownership stake in each business it establishes, and provides funding and central management so that it’s intimately involved at each stage of strategy and growth. Allied Minds currently works with more than 33 leading universities, several of which exceed $1 billion each in annual research spending, as well as 32 federal research centers and laboratories managed by the U.S. Departments of Defense and Energy on a similar commercialization structure. It currently has 18 operating companies in the U.S.